Skip to main content
S&P 5007,553.52-0.51%DOW52,295.750.00%NASDAQ25,125.96-0.95%BTC$68,829.00-3.91%ETH$1,939.38-3.56%GOLD$3,883.70-0.04%OIL$88.92+0.20%
Smart Investors Daily
SID Premium
CD

NASDAQ · CDT

CDT Equity Inc.

Healthcare · Biotechnology

$0.44

Down-$0.03 (-7.15%)

Updated Nov 13, 2026, 5:26 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.44M
P/E ratio
-3.53
Dividend yield
0.00%
52-week range
$0.06 – $12.99
Volume
523.22K
Avg. volume
853.21K

Price performance · CDT

CDT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

CDT closed at $0.44 after 21 trading sessions, up 112.06% for the selected period.

Last close
$0.44
Period change
+112.06%
Period low
$0.07
Period high
$1.40
Daily close
View OHLC price history
CDT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$0.4947$0.5029$0.44$0.4432523.22K
Nov 11, 2026$0.4833$0.56$0.4542$0.511.43M
Nov 10, 2026$0.77$0.77$0.5613$0.5613944.44K
Nov 9, 2026$1.08$1.08$0.821$0.84013.39M
Nov 6, 2026$1.38$1.61$0.981$1.3127.13M
Nov 5, 2026$0.94$0.94$0.78$0.8464.86M
Nov 4, 2026$1.00$1.028$0.934$1.018319.54K
Nov 3, 2026$1.32$1.394$1.204$1.34215.21K
Nov 2, 2026$1.242$1.418$1.08$1.405.3M
Oct 30, 2026$0.0677$0.0699$0.0645$0.0685.39M
Oct 29, 2026$0.077$0.077$0.0685$0.0777.21M
Oct 28, 2026$0.09$0.0916$0.0658$0.083155.32M
Oct 27, 2026$0.089$0.0919$0.076$0.085.3M
Oct 26, 2026$0.1186$0.1186$0.09$0.0946.96M
Oct 23, 2026$0.1316$0.1737$0.1248$0.135.98M
Oct 22, 2026$0.1409$0.1442$0.1282$0.13012.18M
Oct 21, 2026$0.1601$0.161$0.1381$0.14471.72M
Oct 20, 2026$0.1741$0.1776$0.1451$0.1591.92M
Oct 19, 2026$0.1987$0.2086$0.1718$0.1861.35M
Oct 16, 2026$0.1998$0.2423$0.192$0.235111.87M
Oct 15, 2026$0.1972$0.2167$0.1813$0.2092.21M

Latest CDT news

The latest Smart Investors Daily articles mentioning CDT.

Stock researchCompany · Overview

CDT research

Overview

Company profile and research snapshot.

Company profile

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for compounded peptides, which the Company believes is supportive of its strategic investment in Pep’d Inc., a U.S.-based peptide and telehealth company. The U.S. Department of Health and Human Services (“HHS”) has announced an interim enforcement discretion policy covering six peptide bulk

Yahoo · Oct 27, 2026

CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today announced that it has entered into an evaluation agreement with Manoira Corporation ("Manoira"), a specialty animal health company, to assess the potential of CDT's clinical-stage assets AZD1656, including certain proprietary cocrystal derivatives, and AZD5904 to enhance Manoira's forthcoming animal health products. Manoira is preparing to launch its first r

Benzinga · Oct 26, 2026

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC) shares rose

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By